SAN DIEGO, Aug. 12, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three-month period ended June 30, 2013 and provides a business update.
Recent Corporate Highlights
On April 26th, Organovo described the first fully cellular 3D bioprinted liver tissue, having presented data on its in vitro three-dimensional liver at the 2013 Experimental Biology conference in Boston, Massachusetts. For the first time, human liver tissues were generated that were truly three-dimensional, being up to 500 microns in thickness in the smallest dimension, and consisting of multiple cell types arranged in defined spatial patterns that reproduce key elements of native tissue architecture and demonstrated excellent functional characteristics that replicates human biology better than what has come before.
On July 9th, Organovo announced that its common stock had been approved for listing on the New York Stock Exchange MKT. Trading commenced on the NYSE MKT on July 11th, and Company's CEO Keith Murphy rang the opening bell at the NYSE on July 15 th.
On August 7 th, Organovo successfully completed a public offering in which it raised gross pro
|SOURCE Organovo Holdings, Inc.|
Copyright©2012 PR Newswire.
All rights reserved